PMID- 32846826
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 34
DP  - 2020 Aug 21
TI  - The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A 
      PRISMA-compliant systematic review and meta-analysis.
PG  - e21826
LID - 10.1097/MD.0000000000021826 [doi]
LID - e21826
AB  - BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) 
      is the primary treatment in treating with EGFR mutant nonsmall cell lung cancer 
      (NSCLC). This systematic review and meta-analysis aimed to evaluate the efficacy 
      and safety of the third-generation EGFR-TKI, osimertinib, and summarize the risk 
      factors associating with outcome after osimertinib treatment. METHOD: The Ovid 
      Medline, Embase, Cochrane Library, and Pubmed were systematically searched due to 
      December 10, 2019. All the studies that mentioned the overall survival (OS), 
      progression-free survival (PFS), treatment response, and adverse events (AEs) of 
      osimertinib were involved in our study. Hazard ratio (HR) with 95% confidence 
      intervals was used for comparing OS and PFS. RESULT: A total of 47 studies were 
      included in the systematic review, of which 14 studies were used to compare the 
      efficacy between osimertinib and other EGFR-TKI or chemotherapy. Patients 
      treating with osimertinib favors a higher OS and PFS in all the patients 
      (HR = 0.56 and 0.38, P < .001, respectively), and in subgroup analysis, compared 
      with other treatments. Median 55% T790 mutant NSCLC patients might experience 
      partial response, and 25% of patients remained as stable disease. The incidence 
      of severe AE ranged from 0% to 5%, and the most common severe AE was pneumonia 
      (3%). Patients with the T858R mutation may have a better OS than Del 19 mutation 
      (HR = 0.55, P = .037), while patients who have a smoking history may have a 
      higher risk of progression than never-smoker patients (HR = 1.47, P = .028). 
      CONCLUSION: Osimertinib has an impressive antitumor activity compared with prior 
      EGFR-TKI and chemotherapy with an acceptable response and tolerable AEs. EGFR 
      mutation type and smoking status were the risk factors for mortality and 
      progression in NSCLC patients.
FAU - Liu, Jing
AU  - Liu J
AD  - Clinics of Cadre, Department of Outpatient, First Medical Center of Chinese PLA 
      General Hospital, Beijing, China.
FAU - Li, Xuemei
AU  - Li X
FAU - Shao, Yinghong
AU  - Shao Y
FAU - Guo, Xiyun
AU  - Guo X
FAU - He, Jinggui
AU  - He J
AUID- ORCID: 0000-0003-2925-2626
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Acrylamides)
RN  - 0 (Aniline Compounds)
RN  - 0 (Antineoplastic Agents)
RN  - 3C06JJ0Z2O (osimertinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Acrylamides/adverse effects/*therapeutic use
MH  - Aniline Compounds/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics
MH  - Cigarette Smoking
MH  - ErbB Receptors/genetics
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics
MH  - Mutation
MH  - Pneumonia/chemically induced
MH  - Progression-Free Survival
MH  - Survival Rate
PMC - PMC7447427
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/08/28 06:00
MHDA- 2020/09/09 06:00
PMCR- 2020/08/21
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
PHST- 2020/08/21 00:00 [pmc-release]
AID - 00005792-202008210-00080 [pii]
AID - MD-D-20-02680 [pii]
AID - 10.1097/MD.0000000000021826 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 21;99(34):e21826. doi: 
      10.1097/MD.0000000000021826.